Abstract:Background Much effort has been devoted to the discovery of specific mechanisms between drugs and single targets to date. However, as biological systems maintain homeostasis at the level of functional networks robustly controlling the internal environment, such networks commonly contain multiple redundant mechanisms designed to counteract loss or perturbation of a single member of the network. As such, investigation of therapeutics that target dysregulated pathways or processes, rather than single targets, may identify agents that function at a level of the biological organization more relevant to the pathology of complex diseases such as Parkinson’s Disease (PD). Genome-wide association studies (GWAS) in PD have identified common variants underlying disease susceptibility, while gene expression microarray data provide genome-wide transcriptional profiles. These genomic studies can illustrate upstream perturbations causing the dysfunction in signaling pathways and downstream biochemical mechanisms leading to the PD phenotype. We hypothesize that drugs acting at the level of a gene expression module specific to PD can overcome the lack of efficacy associated with targeting a single gene in polygenic diseases. Thus, this approach represents a promising new direction for module-based drug discovery in human diseases such as PD. Results We built a framework that integrates GWAS data with gene co-expression modules from tissues representing three brain regions—the frontal gyrus, the lateral substantia, and the medial substantia in PD patients. Using weighted gene correlation network analysis (WGCNA) software package in R, we conducted enrichment analysis of data from a GWAS of PD. This led to the identification of two over-represented PD-specific gene co-expression network modules: the Br own Module ( Br ) containing 449 genes and the T urquoise module ( T ) containing 905 genes. Further enrichment analysis identified four functional pathways within the Br module (cellular respiration, intracellular transport, energy coupled proton transport against the electrochemical gradient, and microtubule-based movement), and one functional pathway within the T module (M-phase). Next, we utilized drug-protein regulatory relationship databases (DMAP) and developed a D rug E ffect S um S core ( DESS ) to evaluate all candidate drugs that might restore gene expression to normal level across the Br and T modules. Among the drugs with the 12 highest DESS scores, 5 had been reported as potential treatments for PD and 6 hold potential repositioning applications. Conclusion In this study, we present a systems pharmacology framework which draws on genetic data from GWAS and gene expression microarray data to reposition drugs for PD. Our innovative approach integrates gene co-expression modules with biomolecular interaction network analysis to identify network modules critical to the PD pathway and disease mechanism. We quantify the positive effects of drugs in a DESS score that is based on known drug-target activity profiles. Our results illustrate that this modular approach is promising for repositioning drugs for use in polygenic diseases such as PD, and is capable of addressing challenges of the hindered gene target in drug repositioning approaches to date.

MNBDR: A Module Network Based Method for Drug Repositioning

Deep learning identifies explainable reasoning paths of mechanism of action for drug repurposing from multilayer biological network

deepDR: a network-based deep learning approach to in silico drug repositioning

Repositioning Drugs by Targeting Network Modules: a Parkinson's Disease Case Study.

NetPro: Neighborhood Interaction-Based Drug Repositioning Via Label Propagation.

Evaluation of gene-drug common module identification methods using pharmacogenomics data

Prediction of Dynamical Drug Sensitivity and Resistance by Module Network Rewiring-Analysis Based on Transcriptional Profiling

A Pathway Profile-Based Method for Drug Repositioning

Network medicine for disease module identification and drug repurposing with the NeDRex platform

DrugRepPT: a Deep Pre-Training and Fine-Tuning Framework for Drug Repositioning Based on Drug's Expression Perturbation and Treatment Effectiveness.

Network as a Biomarker: A Novel Network-Based Sparse Bayesian Machine for Pathway-Driven Drug Response Prediction

Computational Drug Repositioning with Random Walk on a Heterogeneous Network

DGDRP: drug-specific gene selection for drug response prediction via re-ranking through propagating and learning biological network

Drug Repositioning Through Integration of Prior Knowledge and Projections of Drugs and Diseases

Author Correction: Prediction of New Drug Indications Based on Clinical Data and Network Modularity

Drug repositioning based on comprehensive similarity measures and Bi-Random walk algorithm

A drug repurposing method based on inhibition effect on gene regulatory network

In silico drug repositioning based on drug-miRNA associations

Enhancing Drug Repositioning through Local Interactive Learning with Bilinear Attention Networks

Integration of a prognostic gene module with a drug sensitivity module to identify drugs that could be repurposed for breast cancer therapy.

Drug Repositioning Method Based on Deep Neural Network